Company newsMRNA
Explain this story: UBS reiterates Moderna stock rating ahead of melanoma data
UBS has reiterated a Neutral rating on Moderna Inc. (NASDAQ: MRNA) with a $150.00 price target ahead of anticipated Phase III melanoma trial results. The stock has seen significant movement, trading at $180.30, up over 20% in the past week, and near its 52-week high. The market is keenly awaiting the melanoma study results, expecting a hazard ratio of 0.65 or better, which could lead to a 10-20% stock increase, though InvestingPro analysis suggests the stock is currently overvalued.
OtherInvesting.comSector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
UBS has reiterated a Neutral rating on Moderna Inc. (NASDAQ: MRNA) with a $150.00 price target ahead of anticipated Phase III melanoma trial results. The stock has seen significant movement, trading at $180.30, up over 20% in the past week, and near its 52-week high. The market is keenly awaiting the melanoma study results, expecting a hazard ratio of 0.65 or better, which could lead to a 10-20% stock increase, though InvestingPro analysis suggests the stock is currently overvalued.
Article tone: Neutral This describes the words the journalist used. It is not a prediction, and not advice.
Also mentioned:MRK
Published Sep 22, 2026, 10:13 ET · on this site +4d 15h